MAP2K2: A Protein Regulator of Cell Signaling Pathways (G5605)

Target Name: MAP2K2

NCBI ID: G5605

MAP2K2

MAP2K2: A Protein Regulator of Cell Signaling Pathways

MAP2K2 (mitogen-activated protein kinase kinase 2, p45) is a protein that plays a crucial role in cell signaling pathways. It is a key regulator of theMAPK/ERK signaling pathway, which is involved in a wide range of cellular processes, including cell growth, differentiation, and response to stimuli.

MAP2K2 is a 21-kDa protein that is expressed in most tissues and is highly conserved across species. It is a member of the MAPK/ERK signaling pathway, which is a complex protein-protein interaction network that involves the recruitment of various kinases, phosphatases , and other signaling molecules. The MAPK/ERK pathway is involved in the regulation of many cellular processes, including cell growth, differentiation, angiogenesis, and cell survival.

MAP2K2 is a key regulator of the MAPK/ERK signaling pathway. It is a critical enzyme in the kinase cascade, which is the final step in the MAPK/ERK signaling pathway. The MAP2K2-ERK interaction is critical for the regulation of MAPK/ERK signaling pathway.

MAP2K2 is a protein that can be targeted as a drug or a biomarker. One of the potential strategies for targeting MAP2K2 is to inhibit the MAP2K2-ERK interaction. There are a number of small molecules that have been shown to inhibit the MAP2K2-ERK interaction , and these molecules may be useful as potential drug targets.

Another potential strategy for targeting MAP2K2 is to target the MAP2K2 gene itself. There are several approaches that have been used to modify the expression of MAP2K2, including overexpression, downregulation, and RNA interference. These approaches have been used to knock down the expression of MAP2K2 and to increase its stability.

MAP2K2 is also a protein that is involved in the regulation of cellular processes that are important for the development and progression of cancer. It is a key regulator of cell cycle progression, and it is involved in the regulation of the G1/S transition. MAP2K2 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

In conclusion, MAP2K2 is a protein that plays a crucial role in cell signaling pathways. It is a key regulator of the MAPK/ERK signaling pathway and is involved in the regulation of many cellular processes, including cell growth, differentiation, angiogenesis, and cell survival. As a result, MAP2K2 is a potential drug target and a potential biomarker for the development and progression of cancer. Further research is needed to fully understand the role of MAP2K2 in cellular processes and to develop effective strategies for targeting it.

Protein Name: Mitogen-activated Protein Kinase Kinase 2

Functions: Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation (PubMed:29433126)

The "MAP2K2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP2K2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets